Journal Watch · Nature Chemical Biology · 2026

MESH1 functions as a metazoan PAPS phosphatase to regulate sulfation.

Our biochemical, structural and functional findings establish MESH1 as a key PAPS phosphatase and highlights its potential as a therapeutic target in disorders characterized by sulfation deficiency.

Lin CC, Rose J, Zhang A et al.Nature Chemical Biology3 min readPharma relevance 50/100

DOI: 10.1038/s41589-026-02190-5PMID: 41963701Study type: preclinical (animal / model) study

TL;DR

Our biochemical, structural and functional findings establish MESH1 as a key PAPS phosphatase and highlights its potential as a therapeutic target in disorders characterized by sulfation deficiency.

Key findings

  • Furthermore, in brachymorphic mice, Mesh1 knockout significantly elevates sGAG levels in joint cartilage and improves bone density.
  • In Caenorhabditis elegans lacking bpnt-1, neurotoxic PAP accumulation is alleviated by MESH1 overexpression, reducing upstream PAPS levels.
  • Our biochemical, structural and functional findings establish MESH1 as a key PAPS phosphatase and highlights its potential as a therapeutic target in disorders characterized by sulfation deficiency.

What they did

Our crystallographic analysis of the MESH1-PAPS complex confirms PAPS as a bona fide substrate of MESH1. We further show that MESH1 localizes to Golgi, where sulfotransferases consume PAPS to produce sulfated glycosaminoglycan (sGAG). We show that MESH1 (also known as HDDC3) knockdown enhances sGAG production in a chondrogenic cell line.

Full abstract (original)

Background: Biological sulfation reactions require 3'-phosphoadenosine-5'-phosphosulfate (PAPS) as the universal sulfate donor. While the biosynthetic pathway of PAPS has been well characterized, the phosphatase degrading PAPS remains unidentified. Here, we discover MESH1 as a PAPS phosphatase that hydrolyzes PAPS into adenosine-5'-phosphosulfate and phosphate.

What they did: Our crystallographic analysis of the MESH1-PAPS complex confirms PAPS as a bona fide substrate of MESH1. We further show that MESH1 localizes to Golgi, where sulfotransferases consume PAPS to produce sulfated glycosaminoglycan (sGAG). We show that MESH1 (also known as HDDC3) knockdown enhances sGAG production in a chondrogenic cell line.

Results & conclusions: Furthermore, in brachymorphic mice, Mesh1 knockout significantly elevates sGAG levels in joint cartilage and improves bone density. In Caenorhabditis elegans lacking bpnt-1, neurotoxic PAP accumulation is alleviated by MESH1 overexpression, reducing upstream PAPS levels. Our biochemical, structural and functional findings establish MESH1 as a key PAPS phosphatase and highlights its potential as a therapeutic target in disorders characterized by sulfation deficiency.

Abstract © the authors / Nature Chemical Biology (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1038/s41589-026-02190-5 · PubMed 41963701.

Why it matters for pharma & biotech

  • Directly relevant to teams in cell therapy (CAR-T / engineered cells) — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
  • As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Modalities & themes detected: cell therapy (CAR-T / engineered cells)

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
  • The work is preclinical. Results in animal or cell models frequently do not translate directly to human efficacy or safety.
  • The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.

Frequently asked questions

What did this Nature Chemical Biology study find?

Our biochemical, structural and functional findings establish MESH1 as a key PAPS phosphatase and highlights its potential as a therapeutic target in disorders characterized by sulfation deficiency.

What type of study is this?

It is a preclinical (animal / model) study, published in Nature Chemical Biology in 2026. Our crystallographic analysis of the MESH1-PAPS complex confirms PAPS as a bona fide substrate of MESH1.

Where can I read the original paper?

The original is at the publisher via DOI 10.1038/s41589-026-02190-5. PubMed ID: 41963701. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Lin CC, Rose J, Zhang A et al.. MESH1 functions as a metazoan PAPS phosphatase to regulate sulfation.. Nature Chemical Biology (2026). DOI: 10.1038/s41589-026-02190-5.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/mesh1-functions-as-a-metazoan-paps-phosphatase-to-regulate-sulfation-021905/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides